China Henrikang Factory Supply Vonaprazan / TAK-438 Powder CAS 1260141-27-2 Raw Material
China Henrikang Factory Supply Vonaprazan / TAK-438 Powder CAS 1260141-27-2 Raw Material
Vonaprazan Powder is used for the treatment of erosive esophagitis, gastric ulcers, and duodenal ulcers. It is used for the treatment of acid-related diseases, including refluxEsophagitis (RE), gastric ulcer, duodenal ulcer, prevention of recurrence of gastric ulcer or duodenal ulcer during treatment with low-dose aspirin or NSAIDs, and eradication of H. pylori. TAK-438 Powder eradicates H. pylori and adjuvantly treats the following diseases: gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, early gastric cancer, H. pylori-infected gastritis. China Henrikang Factory Supply Vonaprazan / TAK-438 Powder CAS 1260141-27-2 Raw Material.
- 1, compared with the traditional proton pump inhibitor lansoprazole, Vonoprazan works by competitive and reversible inhibition of K+ in the proton pump. Clinical and animal studies have shown that Vonoprazan has a faster onset of action than PPIs or H2 receptor blockers, has a stronger effect on raising pH, provides rapid relief of GI symptoms, restores enzyme activity after dissociation, has fewer adverse effects, and several Several clinical trials have confirmed that Vonorazan has significant therapeutic effects on erosive esophagitis, prevention and treatment of gastric and duodenal ulcers, and eradication of H. pylori as the first-line treatment option, with higher efficacy than lansoprazole and less adverse effects.
- 2, Vonorazan has high lipophilicity and high dissociation constant, which can be effective in acidic environment without acid activation. The inhibitory effect of Vonorazan on the proton pump does not require acid activation. It enters the stomach at a high concentration and produces the maximum inhibitory effect with the first dose and lasts for 24 hours. Vonorazan is stable in acid and can rapidly raise the pH in the stomach to exert the acid inhibiting effect.
- 3. At therapeutic doses, Vonorazan has little effect on other enzymes, which has little impact on the physiological function of the body and is safe and more easily tolerated. Traditional PPI is metabolized by CYP2C19, but Vonorazan is not mainly metabolized by CYP2C19, so the difference of efficacy and starting dose in different patients is not significant, which can better meet the individualized drug regimen of patients.
Vonoprazan can be used for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
Vonoprazan fumarate shows strong and sustainable acid secretion inhibitory effects as well as demonstrate efficacy in early termination by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pump) in the final step of gastric acid secretion in gastric parietal cells.
